Welcome to our dedicated page for Fortrea Holdings news (Ticker: FTRE), a resource for investors and traders seeking the latest updates and insights on Fortrea Holdings stock.
Fortrea Holdings Inc. reports news on its role as a global contract research organization serving the life sciences industry. The company provides phase I-IV clinical trial management, clinical pharmacology and consulting services for biopharmaceutical, biotechnology, medical device and diagnostic customers.
Recurring Fortrea updates include quarterly and annual financial results, book-to-bill trends, guidance, debt and capital actions, executive and board matters, equity award disclosures and technology used in clinical trial operations. Company announcements also cover platforms such as Fortrea Intelligent Technology and Xcellerate, which support trial workflow, oversight and site-facing processes.
Fortrea (Nasdaq: FTRE) reported second quarter 2026 revenue of $678.2 million, down from $710.3 million in 2025, with a book-to-bill ratio of 1.06x and backlog of $7.8 billion. GAAP net loss was $(13.2) million, or $(0.14) per diluted share, versus a prior-year loss of $(374.9) million that included a large goodwill impairment.
Adjusted net income was $22.7 million (EPS $0.23) and adjusted EBITDA was $58.7 million, both above 2025 levels. First-half 2026 adjusted EBITDA reached $105.7 million. Cash from operations in Q2 was $28.9 million and free cash flow $19.9 million. Fortrea increased full-year 2026 guidance to revenue of $2,620–$2,690 million and adjusted EBITDA of $205–$220 million, reflecting management’s higher outlook for the year.
Fortrea (Nasdaq: FTRE) will release its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026. The company will host a conference call at 8:00 a.m. ET that same day to discuss the results, with access via pre-registration for dial-in details and a unique PIN, and a live webcast and replay available at investors.fortrea.com.
Fortrea (Nasdaq: FTRE) appointed Jason Knoblauch as chief financial officer, effective July 6, 2026, succeeding Jill McConnell, who will support a smooth transition.
The company reaffirmed its full-year 2026 guidance, targeting revenue of $2,550–$2,650 million and adjusted EBITDA of $190–$220 million.
Fortrea (Nasdaq: FTRE) granted an inducement award of 240,500 restricted stock units (RSUs) on June 10, 2026 to 10 newly hired employees.
The RSUs vest in three equal annual installments starting June 10, 2027, under the 2025 Inducement Award Plan and in line with Nasdaq Listing Rule 5635(c)(4).
Fortrea (Nasdaq: FTRE) will participate in the Jefferies Global Healthcare Conference/b) in New York.CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations Tracy Krumme will join a fireside chat on Thursday, June 4, 2026 at 8:45 AM EDT, with a live webcast and replay available.
Fortrea (Nasdaq: FTRE) reported first-quarter 2026 results with revenue of $636.5 million, GAAP net loss of $23.6 million (loss per diluted share $0.25), adjusted net income of $15.2 million (adjusted EPS $0.16) and adjusted EBITDA of $47.0 million. Backlog was $7,846 million and book-to-bill was 1.15x. The company affirmed full-year 2026 guidance of $2,550–$2,650 million revenue and $190–$220 million adjusted EBITDA.
The company will host an earnings call on May 5, 2026, with a replay and supplemental slides available on its Investor Relations website.
Fortrea (Nasdaq: FTRE) will release its first quarter 2026 financial results before the market opens on Tuesday, May 5, 2026.
The company will host a conference call at 8:00 a.m. ET that day; participants should pre-register to receive dial-in details and a unique PIN. A live webcast will be available at investors.fortrea.com, with a replay posted in Events and Presentations after the call.
Fortrea (Nasdaq: FTRE) unveiled Fortrea Intelligent Technology™ (FIT) on April 7, 2026, a suite of AI-enhanced solutions built on the Xcellerate® platform to automate workflows, streamline oversight and deliver near-real-time, role-based insights for sponsors, investigator sites and study teams.
FIT is arranged into three pillars — Lifecycle, Foresight and Companion — and supports clinical pharmacology, clinical development and medical device programs across full-service, functional service and select SaaS deployments.
Fortrea (Nasdaq: FTRE) granted inducement awards of 130,000 restricted stock units (RSUs) on March 10, 2026 to four newly hired employees. The RSUs vest in three equal annual installments beginning March 10, 2027, subject to continuous employment and the Amended and Restated 2025 Inducement Award Plan.
The awards were made under Nasdaq Listing Rule 5635(c)(4) and are intended as an inducement material to each individual becoming a new employee.
Fortrea (Nasdaq: FTRE) reported fourth-quarter 2025 revenue of $660.5M and full-year 2025 revenue of $2,723.4M. GAAP net loss was $(32.5M) in Q4 and $(986.2M) for the year, reflecting a $797.9M goodwill impairment in H1 2025.
Adjusted EBITDA was $54.0M in Q4 and $189.9M for 2025; adjusted net income was $40.4M for the year. Trailing-12-month book-to-bill was 1.02x with backlog of $7,728.0M. Cash was $174.6M and gross debt $1,066.3M. 2026 guidance targets revenue of $2,550M–$2,650M and adjusted EBITDA of $190M–$220M.